GleamWall
中文EN

ARQT Arcutis Biotherapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1787306 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY60.0%
TTM net income YoY167.5%
TTM EPS YoY164.7%
Revenue 3-yr CAGR118.1%
Net income 3-yr CAGR—

Margins

Gross margin91.2%
Operating margin6.9%
Net margin5.9%
FCF margin11.7%
EBITDA margin—

Returns

ROE14.9%
ROA6.7%
ROIC (approx.)10.3%
Asset turnover1.14x

Leverage & solvency

Liabilities / assets53.5%
Debt / equity0.45x
Current ratio2.92x
Interest coverage2.56x

Cash quality & payout

Operating cash flow / net income2.00x
Accruals ratio-6.7%
Payout ratio—
Capex / revenue0.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$143.92M$129.86M$105.40M$129.50M$99.22M$81.50M$65.85M$71.36M
Cost of revenue$12.46M$10.94M$9.78M$11.69M$8.69M$7.49M$8.83M$6.91M
Gross profit$131.46M$118.92M$95.61M$117.81M$90.53M$74.01M$57.02M$64.45M
R&D expense$22.42M$20.36M$30.63M$20.45M$19.60M$19.45M$17.54M$14.48M
SG&A expense$99.60M$82.14M$74.08M$78.98M$62.40M$69.17M$64.00M$57.61M
Operating income$9.44M$16.43M-$9.09M$18.39M$8.53M-$14.61M-$24.53M-$7.63M
Interest expense$2.96M$3.41M$4.37M$3.00M$3.07M$3.03M$2.98M$5.55M
Income tax$195,000$136,000$93,000$470,000$80,000$342,000$279,000$323,000
Net income$8.80M$15.01M-$11.29M$17.39M$7.41M-$15.89M-$25.06M-$10.79M
EBITDA——————-$24.38M-$7.49M
EPS (basic)0.070.11-0.09—0.06-0.13-0.20—
EPS (diluted)0.060.11-0.09—0.06-0.13-0.20—
Weighted avg. shares (diluted)136.84M135.90M129,365—132.88M127.00M126,037—
Balance sheet
Cash & equivalents$33.37M$34.12M$34.76M$42.91M$47.43M$73.05M$53.72M$71.95M
Short-term investments$226.09M$204.43M$189.24M$178.07M$143.95M$118.08M$144.98M$156.62M
Receivables$171.28M$155.16M$144.38M$146.23M$115.12M$106.69M$85.42M$73.07M
Inventory$45.67M$38.88M$37.39M$22.63M$22.42M$16.32M$16.61M$14.53M
Current assets$503.69M$467.67M$438.06M$411.23M$349.22M$332.78M$323.67M$335.82M
PP&E, net$796,000$872,000$1.04M$1.04M$1.22M$1.39M$1.50M$1.04M
Intangibles$13.12M$13.69M$14.25M$14.81M$15.38M$15.94M$16.50M$9.48M
Total assets$524.43M$488.54M$460.00M$432.97M$370.98M$352.43M$344.11M$348.89M
Current liabilities$172.36M$160.34M$163.20M$129.84M$99.77M$103.94M$91.13M$81.01M
Short-term debt$6.95M$6.95M$7.95M$1.00M$1.00M$1.00M—$0
Long-term debt$102.45M$101.95M$101.47M$107.96M$107.50M$107.05M$107.62M$107.20M
Total debt$109.40M$108.90M$109.42M$108.96M$108.50M$108.05M$107.62M$107.20M
Total liabilities$280.46M$267.96M$270.36M$243.49M$212.90M$213.46M$201.45M$191.35M
Shareholders' equity$243.97M$220.58M$189.65M$189.48M$158.07M$138.97M$142.66M$157.54M
Net debt$76.03M$74.78M$74.66M$66.05M$61.07M$35.00M$53.90M$35.25M
Shares outstanding126.02M125.59M125.04M123.33M120.29M119.80M119.14M117.85M
Cash flow statement
Operating cash flow$18.90M$12.64M$2.24M$26.18M-$1.75M$324,000-$30.38M-$748,000
Capital expenditure$97,000$158,000$0$0$0$78,000$608,000$0
Free cash flow$18.80M$12.48M$2.24M$26.18M-$1.75M$246,000-$30.99M-$748,000
Investing cash flow-$22.08M-$15.22M-$11.33M-$34.18M-$25.25M$17.42M$11.75M$34.88M
Financing cash flow$2.45M$1.99M$1.07M$3.72M$1.48M$1.38M$395,000-$97.41M
Depreciation & amortization——————$153,000$145,000
Stock-based compensation$12.36M$12.76M$10.69M$10.06M$10.04M$10.49M$9.78M$9.39M

Free plan shows the latest 8 periods; Pro shows all 31 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.